Page 34 - Read Online

Page 16 of 20 Pellerino et al. J Cancer Metastasis Treat 2020;6:41 I http://dx.doi.org/10.20517/2394-4722.2020.80

9. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012;32:1959-72.
10. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis
2010;37:13-25.
11. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005;2:3-14.
12. Liu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Cancer Cell 2016;30:668-81.
13. Sprowls SA, Arsiwala TA, Bumgarner JR, Shah N, Lateef SS, et al. Improving CNS delivery to brain metastases by blood-tumor barrier
disruption. Trends Cancer 2019;5:495-505.
14. Ota K, Shiraishi Y, Harada T, Himeji D, Kitazaki T, et al. Phase II study of erlotinib in advanced non-small cell lung cancer patients with
leptomeningeal metastasis (LOGIK1101). J Thorac Oncol 2017;12:S271-2.
15. Tamiya A, Tamiya M, Nishihara T, Shiroyama T, Nakao K, et al. Efficacy and cerebrospinal fluid concentration of afatinib in NSCLC
patients with EGFR mutation developing leptomeningeal carcinomatosis. J Thorac Oncol 2017;12:S273.
16. Yang JC, Cho BC, Kim D, Kim SW, Lee JS, et al. Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant
non-small cell lung cancer (NSCLC): updated results from the BLOOM study. Proc Am Soc Clin Oncol 2017;35:2020 (abstr).
17. Nanjo S, Hata A, Okuda C, Kaji R, Okada H, et al. Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-
positive EGFR-mutant non-small cell lung. Br J Cancer 2018;118:32-7.
18. Ahn M, Kim D, Kim TM, Lin CC, Ratnayake J, et al. Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment
of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM). Proc Am Soc Clin Oncol
2016;34:9003 (abstr).
19. Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J
Clin Oncol 2011;29:e443-5.
20. Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet
Oncol 2015;16:e510-21.
21. Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, et al. CH5424802, a selective ALK inhibitor capable of blocking the
resistant gatekeeper mutant. Cancer Cell 2011;19:679-90
22. Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, et al. Antitumor activity of the selective ALK inhibitor alectinib in models
of intracranial metastases. Cancer Chemother Pharmacol 2014;74:1023-8.
23. Solomon B, Bauer TM, Felip E, Besse B, Philip L, et al. Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation
component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol
2016;34:9009 (abstr).
24. Demeule M, Régina A, Jodoin J, Laplante A, Dagenais C, et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein
in the blood-brain barrier. Vascul Pharmacol 2002;38:339-48.
25. Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol 2018;19:e43-55.
26. Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQM. Systemic therapy of brain metastases: non-small cell lung cancer, breast
cancer, and melanoma. Neuro Oncol 2017;19:1-24.
27. Pardridge WM. CSF, blood-brain barrier, and brain drug delivery. Expert Opin Drug Deliv 2016;13:963-75.
28. Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, et al. Phase 0 clinical trials: conceptions and misconceptions. Cancer
J 2008;14:133-7.
29. Arbour KC, Kris MG, Riely GJ, Ni A, Beal K, et al. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for
patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer 2018;124:105-9.
30. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective
in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010;99:283-6.
31. Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, et al. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR
mutant non-small cell lung cancer. Neuro Oncol 2011;13:1364-9.
32. Wang S, Chen J, Xie Z, Xia L, Luo W, et al. Pulsatile crizotinib treatment for brain metastasis in a patient with non-small-cell lung cancer.
J Clin Pharm Ther 2017;42:627-30.
33. Pellerino A, Bertero L, Rudà R, Soffietti R. Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments. Ther Adv
Neurol Disord 2018;11:1756286418759618.
34. Roelz R, Reinacher P, Jabbarli R, Kraeutle R, Hippchen B, et al. Surgical ventricular entry is a key risk factor for leptomeningeal
metastasis of high grade gliomas. Sci Rep 2015;5:17758.
35. Ahn JH, Lee SH, Kim S, Shin SH, Gwak HS, et al. Risk for leptomeningeal seeding after resection for brain metastases: implication of
tumor location with mode of resection. J Neurosurg 2012;116:984-93.
36. Ojerholm E, Lee JY, Thawani JP, Miller D, Alonso-Basanta M, et al. Stereotactic radiosurgery to the resection bed for intracranial
metastases and risk of leptomeningeal carcinomatosis. J Neurosurg 2014;121:75-83.
37. Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, et al. Post-operative stereotactic radiosurgery versus observation for completely
resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 2017;18:1040-8.
38. Foreman PM, Jackson BE, Singh KP, Romeo AK, Guthrie B, et al. Postoperative radiosurgery for the treatment of metastatic brain tumor:
Evaluation of local failure and leptomeningeal disease. J Clin Neurosci 2018;49:48-55.
39. Boire A, Zou Y, Shieh J, Macalinao DG, Pentsova E, et al. Complement component 3 adapts the cerebrospinal fluid for leptomeningeal
metastasis. Cell 2017;168:1101-13.e13.
40. Conrad C, Dorzweiler K, Miller MA, Lauffenburger DA, Strik H, et al. Profiling of metalloprotease activities in cerebrospinal fluids of